Chai Discovery
Chai Discovery develops AI models for designing molecules, including Chai-2 for de novo antibody and miniprotein design against a chosen target. It gives commercial organizations access on request, plans limited non-commercial use, and lists a Novartis collaboration and a Pfizer license agreement.
Product
Selected offerings — the AI products recorded here, not the vendor's full catalogue.
-
Chai Discovery platform Platform
Molecular structure prediction and design tools for antibody and protein engineering.
Closest alternatives 2
Similar products 11
Closest alternatives are pairs a vendor page itself compares. Similar products are matched from what each product does; nothing in that group is asserted as a rivalry.
Sources
- Total funding
-
Chai brews up $400M series C to fuel AI molecule models used by Lilly, Novartis and Pfizer, Fierce Biotech, July 14, 2026. Read via stockanalysis.com's citation for this figure on 2026-08-27.
- Stage, from valuation
-
Series C: Announcing our $400M fundraise, Chai Discovery, 2026-07-14. post-money valuation of the round dated 2026-07-14. Read via stockanalysis.com's citation for this figure on 2026-08-27.
- Founded
-
"Chai was founded in 2024 by Joshua Meier..., Jack Dent..., and AI researchers Matthew McPartlon and Jacques Boitreaud."
Open Chai Discovery in the directory
Something wrong here? Send a correction — quote this company id: chai-discovery.